Skip to main content
. Author manuscript; available in PMC: 2009 Sep 28.
Published in final edited form as: Nature. 2007 Nov 29;450(7170):712–716. doi: 10.1038/nature06261

Figure 4. SIRT1 activator SRT1720 in the Zucker fa/fa rat model.

Figure 4

a, Post-absorptive blood glucose (3 weeks). b, c, Glucose and insulin responses during an oral glucose tolerance test (3.5 weeks, ANOVA). After 4 weeks a hyperinsulinaemic-euglycaemic clamp study was conducted. (d—f) Glucose infusion rate (GIR), glucose disposal rate (GDR) and insulin-stimulated glucose disposal rate (IS-GDR) were significantly enhanced. g, Hepatic glucose output (HGO) suppression (%). h, Plasma fatty acid concentration during the clamp was significantly lower in SRT1720-treated animals (ANOVA). B, basal conditions. C, clamp conditions. i, Glucose excursion during a PTT was reduced, indicating reduced gluconeogenic capacity. All studies consisted of n ≥ 5 rats per group. Statistics were conducted as student t-test unless noted otherwise; asterisk P < 0.05, double asterisk P < 0.01, and triple asterisk P < 0.001. Data are expressed as mean ± s.e.m.